ReviewNutrients2022
Contribution of Advanced Glycation End Products to PCOS Key Elements: A Narrative Review.
Review in Nutrients, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 41 citations in OpenAlex.
- Exploring heart rate variability in polycystic ovary syndrome: implications for cardiovascular health: a systematic review and meta-analysis.Systematic reviews · 2024Pooled it
- Exploratory pilot trial of astaxanthin supplementation in PCOS patients at risk of OHSS with focus on RAGE-NFκB pathway.Scientific reports · 2026Trial
- Comparison of Metabolic and Hormonal Profiles between Low-Advanced Glycation End Products (AGEs) and Standard AGEs-Containing Weight-Loss Diets in Overweight Phenotype-A PCOS Patients: A Randomized Clinical Trial.Reproductive sciences (Thousand Oaks, Calif.) · 2025Trial
- Heat-processed rodent chow alters nutritive content and improves metabolic outcomes in insulin-resistant female mice.Frontiers in nutrition · 2026Article
- Unraveling mitochondrial dysfunction in polycystic ovary syndrome: Pathophysiological insights.Journal of the Chinese Medical Association : JCMA · 2025Review
- The Role of Diet in Women of Childbearing Age: Current Evidence Supporting Nutritional Recommendations.Nutrients · 2025Review
- Are Dietary and Serum Advanced Glycation End Products (AGEs) Potential Contributors to Inflammation in Women with Polycystic Ovary Syndrome?Journal of clinical medicine · 2025Article
- Assessment and prediction models for the quantitative and qualitative reserve of the ovary using machine learning.Journal of ovarian research · 2025Article
- Article
- The associations between dietary advanced glycation-end products intake and self-reported infertility in U.S. women: data from the NHANES 2013-2018.Scientific reports · 2025Article
- Cardiovascular Risk Biomarkers in Women with and Without Polycystic Ovary Syndrome.Biomolecules · 2024Article
- Recent Trends in Advanced Glycation End Products in Foods: Formation, Toxicity, and Innovative Strategies for Extraction, Detection, and Inhibition.Foods (Basel, Switzerland) · 2024Review
- Advanced Glycation End-Products of Follicular Fluid are Associated with Embryo Morphokinetic Parameters and ART Outcomes.Reproductive sciences (Thousand Oaks, Calif.) · 2024Article
- CAPN2 correlates with insulin resistance states in PCOS as evidenced by multi-dataset analysis.Journal of ovarian research · 2024Article
- A review of nitric oxide and oxidative stress in typical ovulatory women and in the pathogenesis of ovulatory dysfunction in PCOS.Reproductive biology and endocrinology : RB&E · 2023Review
- Review
- Roles of endoplasmic reticulum stress in the pathophysiology of polycystic ovary syndrome.Frontiers in endocrinology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the last decade, data has suggested that dietary advanced glycation end products (AGEs) play an important role in both reproductive and metabolic dysfunctions associated with polycystic ovary syndrome (PCOS). AGEs are highly reactive molecules that are formed by the non-enzymatic glycation process between reducing sugars and proteins, lipids, or nucleic acids. They can be formed endogenously under normal metabolic conditions or under abnormal situations such as diabetes, renal disease, and other inflammatory disorders. Bodily AGEs can also accumulate from exogenous dietary sources particularly when ingested food is cooked and processed under high-temperature conditions, such as frying, baking, or grilling. Women with PCOS have elevated levels of serum AGEs that are associated with insulin resistance and obesity and that leads to a high deposition of AGEs in the ovarian tissue causing anovulation and hyperandrogenism. This review will describe new data relevant to the role of AGEs in several key elements of PCOS phenotype and pathophysiology. Those elements include ovarian dysfunction, hyperandrogenemia, insulin resistance, and obesity. The literature findings to date suggest that targeting AGEs and their cellular actions could represent a novel approach to treating PCOS symptoms.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.